Cancerify Logo
Log inSign up
Back to clinical trials
RecruitingInterventionalPhase 3

Phase III Study of Local or Systemic Therapy INtensification DIrected by PET in Prostate CAncer Patients With Post-ProstaTEctomy Biochemical Recurrence (INDICATE)

NCT ID: NCT04423211Sponsor: ECOG-ACRIN Cancer Research GroupLast updated: 2026-06-18

Summary

This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation therapy and short term androgen deprivation) is more effective compared to standard of care alone in patients with prostate cancer who experience biochemical recurrence (a rise in the blood level of prostate specific antigen \[PSA\] after surgical removal of the prostate cancer). A second question tests treatment in patients with biochemical recurrence who show prostate cancer spreading outside the pelvis (metastasis) by positron emission tomography (PET) imaging. In these patients, the benefit of adding metastasis-directed radiation to enhanced therapy (apalutamide in combination with abiraterone + prednisone) is tested. Diagnostic procedures, such as PET, may help doctors look for cancer that has spread to the pelvis. Androgens are hormones that may cause the growth of prostate cancer cells. Apalutamide may help fight prostate cancer by blocking the use of androgens by the tumor cells. Metastasis-directed targeted radiation therapy uses high energy rays to kill tumor cells and shrink tumors that have spread. This trial may help doctors determine if using PET results to deliver more tailored treatment (i.e., adding apalutamide, with or without targeted radiation therapy, to standard of care treatment) works better than standard of care treatment alone in patients with biochemical recurrence of prostate cancer.

Detailed description

PRIMARY OBJECTIVES: I. For patients without PET-evidence of extrapelvic metastases, to evaluate whether the addition of enhanced systemic therapy to standard of care (SOC) salvage radiation therapy (RT) could prolong progression-free survival (PFS). II. For patients with PET-evidence of extrapelvic metastases, to evaluate whether the addition of metastasis-directed RT to enhanced systemic therapy and SOC salvage RT could prolong PFS. III. To compare overall quality of life, measured by Functional Assessment of Cancer Therapy - Prostate (FACT-P) total score, at 6 months between the two sets of treatment arms (A with B and C with D). (QUALITY OF LIFE \[QOL\] OBJECTIVE) SECONDARY OBJECTIVES: I. To evaluate overall survival in each arm. II. To evaluate event-free survival in each arm. III. To evaluate time to prostate-specific antigen (PSA) progression in each arm. IV. To assess the incidence of adverse events with the addition of enhanced systemic therapy in patients without PET-evidence of extrapelvic metastases. V. To assess the incidence of adverse events with local ablative metastasis-directed RT for PET-positive metastatic disease in patients with PET-evidence of extrapelvic metastases. VI. To estimate the detection rate of PET at the patient and regional level, and to evaluate its concordance with the follow-up Food and Drug Administration (FDA)-approved conventional imaging modalities (CIM) (as available) considered standard-of-care per institution, including computed tomography (CT), bone scintigraphy, magnetic resonance imaging (MRI) and PET imaging. VII. To determine the distribution of PET-positive lesions among anatomic sites (prostate fossa, intrapelvic soft tissue/lymph node, extrapelvic soft tissue/lymph node, and bone metastases) in patients with post-radical prostatectomy (RP) biochemical recurrence (BCR), correlated with PSA (level, doubling time, velocity) and other relevant clinical parameters. VIII. To compare the change in overall QOL, measured by FACT-P total score, from baseline to 6 months between the two sets of treatment arms (A with B and C with D). (QOL OBJECTIVE) IX. To compare patient-reported fatigue (Functional Assessment of Chronic Illness Therapy \[FACIT\]-Fatigue scores) at 6 months between the two sets of treatment arms (A with B and C with D). (QOL OBJECTIVE) X. To compare patient-reported overall QOL (FACT-P scores), fatigue (FACIT-Fatigue scores) and pain interference (patient reported outcomes measurement information system \[PROMIS\] Pain Interference Short Form 4a) between the two sets of treatment arms (A with B and C with D) at the time of disease progression. (QOL OBJECTIVE) EXPLORATORY OBJECTIVES: I.To determine the value of repeat PET (PET2) at time of second PSA progression, clinical concern for progression, or 12 months after completion of enhanced systemic therapy, whichever comes first to assess response to therapy (enhanced systemic therapy +/- focal RT and/or androgen deprivation therapy \[ADT\]) compared to available standard response assessments (PSA and conventional imaging modalities \[CIM\]). II. To compare cognitive function, measured by FACT - cognitive function (Cog) peritoneal cancer index (PCI) and total scores, between the three treatment arms receiving enhanced systemic treatment with ADT and apalutamide (Arms B, C, and D) and antiandrogen therapy (ADT) alone (Arm A) at 6 and 12 month. (QOL OBJECTIVE) III. To compare the change in cognitive function, measured by change in FACT-Cog PCI and total scores, from baseline to 6 and baseline to 12 months, between the three treatment arms receiving enhanced systemic treatment with ADT and apalutamide (Arms B, C, and D) and ADT alone (Arm A) at 6 and 12 months. (QOL OBJECTIVE) IV. To characterize longitudinal change in cognitive function between baseline and 24 months in patients with prostate cancer receiving treatment for biochemical recurrence (BCR) and define clinical and disease related characteristics associated with greater cognitive change by the FACT-Cog PCI and total scores. (QOL OBJECTIVE) OUTLINE: STEP 0: Patients undergo SOC PET/CT or PET/MR scan at baseline. Patients randomized to Arms C or D and receiving fluciclovine F18 intravenously (IV) undergo a repeat PET2 at time of PSA progression or clinical concerns for progression or 12 months after completion of enhanced systemic therapy, whichever occurs first. Patients in Arm C or D using another tracer for PET1 do not undergo PET2. STEP 1: Patients are randomized to 1 of 4 arms based on results of fluciclovine F18 PET/CT or PET/MR in Step 0. ARM A (PET NEGATIVE FOR EXTRA PELVIC-METASTASES): Patients undergo SOC external beam radiation therapy (EBRT) for 6 months. Patients also receive goserelin acetate subcutaneously (SC), leuprolide acetate intramuscularly (IM), triptorelin IM, relugolix orally (PO), or degarelix SC for 6 months starting up to 3 months prior to EBRT but no later than 7 days after start of EBRT. All treatment continues for 6 months in the absence of disease progression or unacceptable toxicity. ARM B (PET NEGATIVE FOR EXTRA PELVIC-METASTASES): Patients undergo SOC EBRT and receive goserelin acetate SC, leuprolide acetate IM, triptorelin IM, relugolix PO, or degarelix SC as in Arm A. Patients also receive apalutamide PO once daily (QD) for 6 months in the absence of disease progression or unacceptable toxicity. ARM C: (PET POSITIVE FOR EXTRA PELVIC-METASTASES): Patients undergo SOC EBRT and receive goserelin acetate SC, leuprolide acetate IM, triptorelin IM, relugolix PO, or degarelix SC as in Arm A. Patients also receive apalutamide PO QD as in Arm B. ARM D (PET POSITIVE FOR EXTRA PELVIC-METASTASES): Patients undergo SOC EBRT and receive goserelin acetate SC, leuprolide acetate IM, triptorelin IM, relugolix PO, or degarelix SC as in Arm A and apalutamide PO QD as in Arm B. Patients also undergo stereotactic body radiation therapy (SBRT) or 3-dimensional (3D) conformal radiation therapy (CRT), intensity-modulated radiation therapy (IMRT) (including volume modulated arc therapy \[VMAT\]), and intensity-modulated proton therapy (IMPT) over 3-10 fractions in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 3 months for the first 2 years, every 6 months for years 3-5, and then annually for years 6-10.

Arms & interventions

  • Radiation3-Dimensional Conformal Radiation Therapy

    Undergo 3D CRT

  • DrugApalutamide

    Given PO

  • ProcedureComputed Tomography

    Undergo PET/CT

  • DrugDegarelix

    Given SC

  • RadiationExternal Beam Radiation Therapy

    Undergo EBRT

  • OtherFluciclovine F18

    Given IV

  • DrugGoserelin Acetate

    Given SC

  • ProcedureIntensity-Modulated Proton Therapy

    Undergo IMPT

  • RadiationIntensity-Modulated Radiation Therapy

    Undergo IMRT

  • DrugLeuprolide Acetate

    Given IM

  • ProcedureMagnetic Resonance Imaging

    Undergo PET/MR

  • ProcedurePositron Emission Tomography

    Undergo PET/CT or PET/MR

  • OtherQuality-of-Life Assessment

    Ancillary studies

  • OtherQuestionnaire Administration

    Ancillary studies

  • DrugRelugolix

    Given PO

  • RadiationStereotactic Body Radiation Therapy

    Undergo SBRT

  • DrugTriptorelin

    Given IM

  • RadiationVolume Modulated Arc Therapy

    Undergo VMAT

Outcome measures

Primary

  • Progression-free survival (PFS)

    The power of the PFS analysis is 85% using one-sided 0.025 level stratified logrank test. The overall type I error will be controlled using an O'Brien-Fleming boundary function

    Time frame: From randomization to radiographic progression by conventional imaging or positron emission tomography (PET), symptomatic disease or death, whichever occurs first, assessed up to 10 years

  • PFS prolongation in patients without PET-evidence of extrapelvic metastases

    Will evaluate whether the addition of enhanced systemic therapy to standard of care salvage therapy could prolong PFS in this patient population. Will be an intention-to-treat analysis of all randomized patients and performed in parallel with patients with PET-evidence of extrapelvic metastases.

    Time frame: Up to 10 years

  • PFS prolongation in patients with PET-evidence of extrapelvic metastases

    Will evaluate whether the addition of metastasis-directed radiation therapy to standard of care salvage therapy and enhanced systemic therapy could prolong PFS in this patient population. Will be an intention-to-treat analysis of all randomized patients and performed in parallel without patients with PET-evidence of extrapelvic metastases.

    Time frame: Up to 10 years

  • Quality of life (QOL)

    Descriptive statistics will be used to characterize QOL over time in each arm.

    Time frame: Up to 24 months

Secondary

  • Overall survival (OS)

    Time frame: From randomization to death or date last known alive, assessed up to 10 years

  • Event-free survival

    Time frame: From randomization to radiographic progression by conventional imaging or PET, symptomatic disease, or initiation of new treatment for the disease or death, whichever occurs first, assessed up to 10 years

  • Time to prostate-specific antigen (PSA) progression

    Time frame: From randomization to documented PSA progression or radiographic progression, whichever occurs first, assessed up to 10 years

  • Incidence of adverse events

    Time frame: Up to 10 years

  • Detection rate of fluciclovine F18 (18F-fluciclovine) PET

    Time frame: At time of PSA recurrence, as clinically indicated or 12 months after completion of enhanced systemic therapy (whichever occurs first), assessed up to 10 years

  • Concordance of detection rate with the follow-up conventional imaging modalities (CIM)

    Time frame: At time of PSA recurrence, as clinically indicated or 12 months after completion of enhanced systemic therapy (whichever occurs first), assessed up to 10 years

  • Distribution of 18F-fluciclovine PET-positive lesions among anatomic sites

    Time frame: Baseline

  • Value of repeat PET to assess response to therapy compared to standard response assessments

    Time frame: At time of second PSA recurrence or 12 months after completion of enhanced systemic therapy (whichever occurs first), assessed up to 10 years

  • Comparison - Functional Assessment of Cancer Therapy (FACT)- prostate (P)

    Time frame: At baseline and 3, 6, 9, 12 months

  • Change in FACT-P and Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue

    Time frame: Baseline up to 6 months

  • QOL Assessments at Progression

    Time frame: Up to 10 years

  • FACT- cognitive functioning (Cog)

    Time frame: Up to 12 months

Eligibility criteria

Sex: MaleAge: 18 Years and olderHealthy volunteers: No
Inclusion Criteria: * STEP 0: REGISTRATION ELIGIBILITY CRITERIA * Patient must be male and \>= 18 years of age. * Patient must have had a radical prostatectomy (RP) as definitive therapy for histopathologically-proven prostatic adenocarcinoma * Patient must have biochemical recurrence (BCR) after RP, defined as follows: * If time to BCR, defined as time to first detectable PSA ( \> lower limit of normal for assay used) after RP, is \< 12 months, a minimum PSA level of \>= 0.2 ng/mL and a confirmatory reading of \>= 0.2 ng/mL is required, per the American Urological Association (AUA) definition (Note: patients with a persistent PSA reading of at least 0.2 ng/mL are eligible) * If time to BCR, defined as time to first detectable PSA (\> lower limit of normal for assay used) after RP, is \>= 12 months, a minimum absolute PSA of 0.5 ng/mL is required * If the patient has a detectable PSA (\> lower limit of normal for assay used) at any time after RP AND has an eligible baseline SOC PET (PET1) with at least one positive lesion in any location, then there is no minimum PSA requirement * Patients must have no definite evidence for extrapelvic metastatic disease by conventional imaging modalities (CIM) (CT abdomen/pelvis or MRI abdomen/pelvis AND bone scintigraphy, or equivalent), within 26 weeks prior to Step 0 registration. If a patient only has a study-eligible PET/CT or PET/MR (i.e., PET done without prior CIM): if the PET is negative for extrapelvic lesions, then baseline CIM is NOT required. If the PET positive for extrapelvic lesions, then patient should have a baseline CT/MRI for soft tissue lesions and/or a bone scan for osseous lesions * Study eligible = PET using FDA-approved radiotracer and performed within 16 weeks prior to study registration * Extra-pelvic metastases is defined as any osseous metastases and/or any extrapelvic soft tissue, lymph nodes and organ metastases; extra-pelvic is defined as superior to common iliac bifurcation, outside of standard prostate bed + whole pelvis nodal RT fields. Baseline PET/CT or PET/MR scan (PET1) is eligible for this study if the SOC PET scan is completed with an FDA approved radiotracer for prostate cancer after Step 0 registration and prior to Step 1 randomization OR up to 16 weeks prior to Step 0 registration * Patient must be a candidate for SOC post-prostatectomy radiation therapy (RT) to the prostate bed and pelvic nodes with androgen deprivation therapy (ADT) * Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available will also be considered eligible * Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status 0-2 * Patient must not have started ADT for biochemical recurrence prior to baseline PET (PET1) imaging. A short course of low-dose anti-androgen such as bicalutamide, given after baseline study PET/CT but prior to study registration, is permitted as a brief temporizing measure in advance of starting protocol-approved SOC ADT. * Patient must not be enrolled in another therapeutic clinical trial * Patient must be able to lie flat and still for approximately 20-30 minutes or otherwise tolerate a PET scan and radiation treatment planning and delivery * Patients undergoing a PET/MR must meet local institutional safety guidelines for MRI * Patient must not have history of seizures or known condition that may cause predisposal to seizures (e.g., stroke or head trauma resulting in loss of consciousness) within 1 year prior to registration * Patient must not have history of inflammatory bowel disease or any gastrointestinal disorder affecting absorption that is expected to increase risk of complication from radiotherapy * Hemoglobin (Hgb) \>= 9.0 g/dL (independent of transfusion and/or growth factors within 3 months prior to Step 0 registration) (obtained within 8 weeks prior to Step 0 registration) * Leukocytes \>= 3,000/mcL (obtained within 8 weeks prior to Step 0 registration) * Absolute neutrophil count \>= 1,500/mcL (obtained within 8 weeks prior to Step 0 registration) * Platelets \>= 100,000/mcL (obtained within 8 weeks prior to Step 0 registration) * Total bilirubin \< 1.5 x institutional upper limit of normal (ULN) (patients with Gilbert's syndrome, if total bilirubin is \> 1.5 x ULN, must have a direct bilirubin of \< 1.5 x ULN to be eligible) (obtained within 8 weeks prior to Step 0 registration) * Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) =\< 2.5 x institutional ULN (obtained within 8 weeks prior to Step 0 registration) * Creatine \< 1.5 x instituional ULN (or measured creatinine clearance \> 30 mL/min) * Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial * Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class I or II (by patient symptoms) or A or B (by objective assessment) * Patient must not have completed a course of prior pelvic radiation therapy for any reason * Patient must agree not to father children while on study * Patient must be English or Spanish speaking to be eligible for the QOL component of the study * NOTE: Sites cannot translate the associated QOL forms * STEP 1: RANDOMIZATION ELIGIBILITY CRITERIA * Patient must have completed a baseline SOC PET/CT or PET/MR (PET1 scan) using FDA approved radiotracer with results of extra-pelvic metastases involvement known (positive or negative). The PET1 must have been completed after Step 0 registration and prior to Step 1 randomization OR up to 12 weeks prior to Step 0 registration * For patients with negative extra-pelvic metastases, PET-imaging status of intra-pelvic nodes must be known (positive or negative) * For patients with positive extra-pelvic metastases (defined as any PET positive lesions outside of standard salvage RT fields \[prostate bed +/- typical whole pelvis\]), the number of extra-pelvic lesions must be known (1 - 5 or \> 5 extra-pelvic lesions)

Study locations (342)

Anchorage Associates in Radiation Medicine

Anchorage, Alaska, 98508

Recruiting
Site Public Contact · Contact
907-212-6871AKPAMC.OncologyResearchSupport@providence.org
Alison K. Conlin · Principal Investigator

Alaska Breast Care and Surgery LLC

Anchorage, Alaska, 99508

Recruiting
Site Public Contact · Contact
907-212-6871AKPAMC.OncologyResearchSupport@providence.org
Alison K. Conlin · Principal Investigator

Alaska Oncology and Hematology LLC

Anchorage, Alaska, 99508

Recruiting
Site Public Contact · Contact
907-212-6871AKPAMC.OncologyResearchSupport@providence.org
Alison K. Conlin · Principal Investigator

Alaska Women's Cancer Care

Anchorage, Alaska, 99508

Recruiting
Site Public Contact · Contact
907-212-6871AKPAMC.OncologyResearchSupport@providence.org
Alison K. Conlin · Principal Investigator

Anchorage Oncology Centre

Anchorage, Alaska, 99508

Suspended

Katmai Oncology Group

Anchorage, Alaska, 99508

Recruiting
Site Public Contact · Contact
907-212-6871AKPAMC.OncologyResearchSupport@providence.org
Alison K. Conlin · Principal Investigator

Providence Alaska Medical Center

Anchorage, Alaska, 99508

Recruiting
Site Public Contact · Contact
907-212-6871AKPAMC.OncologyResearchSupport@providence.org
Alison K. Conlin · Principal Investigator

Fairbanks Memorial Hospital

Fairbanks, Alaska, 99701

Suspended

Cancer Center at Saint Joseph's

Phoenix, Arizona, 85004

Recruiting
Site Public Contact · Contact
720-874-1881ResearchInstituteInquiries@CommonSpirit.org
Shahzad Siddique · Principal Investigator

Mercy Hospital Fort Smith

Fort Smith, Arkansas, 72903

Recruiting
Site Public Contact · Contact
800-378-9373
Jay W. Carlson · Principal Investigator

Mission Hope Medical Oncology - Arroyo Grande

Arroyo Grande, California, 93420

Recruiting
Site Public Contact · Contact
720-874-1881ResearchInstituteInquiries@CommonSpirit.org
Shahzad Siddique · Principal Investigator

Providence Saint Joseph Medical Center/Disney Family Cancer Center

Burbank, California, 91505

Recruiting
Site Public Contact · Contact
818-847-4793Najee.Boucher@providence.org
Alison K. Conlin · Principal Investigator

Mercy Cancer Center - Carmichael

Carmichael, California, 95608

Recruiting
Site Public Contact · Contact
720-874-1881ResearchInstituteInquiries@CommonSpirit.org
Shahzad Siddique · Principal Investigator

Mercy San Juan Medical Center

Carmichael, California, 95608

Recruiting
Site Public Contact · Contact
916-556-3301OncologyResearch@DignityHealth.org
Shahzad Siddique · Principal Investigator

City of Hope Corona

Corona, California, 92882

Recruiting
Site Public Contact · Contact
626-256-4673becomingapatient@coh.org
Scott M. Glaser · Principal Investigator

City of Hope Comprehensive Cancer Center

Duarte, California, 91010

Recruiting
Scott M. Glaser · Contact
626-218-2247sglaser@coh.org
Scott M. Glaser · Principal Investigator

Mercy Cancer Center - Elk Grove

Elk Grove, California, 95758

Recruiting
Site Public Contact · Contact
720-874-1881ResearchInstituteInquiries@CommonSpirit.org
Shahzad Siddique · Principal Investigator

UC San Diego Health System - Encinitas

Encinitas, California, 92024

Recruiting
Site Public Contact · Contact
760-536-7700
James M. Randall · Principal Investigator

UC San Diego Moores Cancer Center

La Jolla, California, 92093

Recruiting
Site Public Contact · Contact
858-822-5354cancercto@ucsd.edu
James M. Randall · Principal Investigator

City of Hope Antelope Valley

Lancaster, California, 93534

Recruiting
Site Public Contact · Contact
800-826-4673becomingapatient@coh.org
Scott M. Glaser · Principal Investigator

Los Angeles General Medical Center

Los Angeles, California, 90033

Active Not Recruiting

USC / Norris Comprehensive Cancer Center

Los Angeles, California, 90033

Active Not Recruiting

UCLA / Jonsson Comprehensive Cancer Center

Los Angeles, California, 90095

Recruiting
Site Public Contact · Contact
888-798-0719
Amar Kishan · Principal Investigator

Mercy Cancer Center

Merced, California, 95340

Suspended

VA Palo Alto Health Care System

Palo Alto, California, 94304

Active Not Recruiting

Mercy Cancer Center - Rocklin

Rocklin, California, 95765

Recruiting
Site Public Contact · Contact
720-874-1881ResearchInstituteInquiries@CommonSpirit.org
Shahzad Siddique · Principal Investigator

Mercy Cancer Center - Sacramento

Sacramento, California, 95816

Recruiting
Site Public Contact · Contact
720-874-1881ResearchInstituteInquiries@CommonSpirit.org
Shahzad Siddique · Principal Investigator

UC San Diego Medical Center - Hillcrest

San Diego, California, 92103

Recruiting
Site Public Contact · Contact
rhabbaba@health.ucsd.edu
James M. Randall · Principal Investigator

Pacific Central Coast Health Center-San Luis Obispo

San Luis Obispo, California, 93401

Recruiting
Site Public Contact · Contact
720-874-1881ResearchInstituteInquiries@CommonSpirit.org
Shahzad Siddique · Principal Investigator

Mission Hope Medical Oncology - Santa Maria

Santa Maria, California, 93444

Recruiting
Site Public Contact · Contact
720-874-1881ResearchInstituteInquiries@CommonSpirit.org
Shahzad Siddique · Principal Investigator

City of Hope South Pasadena

South Pasadena, California, 91030

Recruiting
Site Public Contact · Contact
800-826-4673becomingapatient@coh.org
Scott M. Glaser · Principal Investigator

Saint Joseph's Medical Center

Stockton, California, 95204

Recruiting
Site Public Contact · Contact
209-461-5257
Shahzad Siddique · Principal Investigator

City of Hope Upland

Upland, California, 91786

Recruiting
Site Public Contact · Contact
800-826-4673becomingapatient@coh.org
Scott M. Glaser · Principal Investigator

BASS Medical Group - Lennon

Walnut Creek, California, 94598

Active Not Recruiting

Woodland Memorial Hospital

Woodland, California, 95695

Recruiting
Site Public Contact · Contact
720-874-1881ResearchInstituteInquiries@CommonSpirit.org
Shahzad Siddique · Principal Investigator

Rocky Mountain Cancer Centers-Aurora

Aurora, Colorado, 80012

Active Not Recruiting

Rocky Mountain Cancer Centers-Boulder

Boulder, Colorado, 80304

Active Not Recruiting

Penrose-Saint Francis Healthcare

Colorado Springs, Colorado, 80907

Recruiting
Site Public Contact · Contact
720-874-1881ResearchInstituteInquiries@CommonSpirit.org
Shahzad Siddique · Principal Investigator

Rocky Mountain Cancer Centers-Penrose

Colorado Springs, Colorado, 80907

Recruiting
Site Public Contact · Contact
720-874-1881ResearchInstituteInquiries@CommonSpirit.org
Shahzad Siddique · Principal Investigator

Saint Francis Cancer Center

Colorado Springs, Colorado, 80923

Recruiting
Site Public Contact · Contact
720-874-1881ResearchInstituteInquiries@CommonSpirit.org
Shahzad Siddique · Principal Investigator

AdventHealth Porter

Denver, Colorado, 80210

Suspended

Presbyterian - Saint Lukes Medical Center - Health One

Denver, Colorado, 80218

Active Not Recruiting

Dillon Health Center/Shaw Cancer Center

Dillon, Colorado, 80435

Recruiting
Site Public Contact · Contact
970-470-7170
Erin Schwab · Principal Investigator

Shaw Cancer Center

Edwards, Colorado, 81632

Recruiting
Site Public Contact · Contact
970-569-7429
Erin Schwab · Principal Investigator

The Melanoma and Skin Cancer Institute

Englewood, Colorado, 80113

Active Not Recruiting

Saint Anthony Hospital

Lakewood, Colorado, 80228

Recruiting
Site Public Contact · Contact
720-874-1881ResearchInstituteInquiries@CommonSpirit.org
Shahzad Siddique · Principal Investigator

Rocky Mountain Cancer Centers-Littleton

Littleton, Colorado, 80120

Active Not Recruiting

AdventHealth Littleton

Littleton, Colorado, 80122

Suspended

Longmont United Hospital

Longmont, Colorado, 80501

Recruiting
Site Public Contact · Contact
720-874-1881ResearchInstituteInquiries@CommonSpirit.org
Shahzad Siddique · Principal Investigator

AdventHealth Parker

Parker, Colorado, 80138

Suspended

Saint Mary Corwin Medical Center

Pueblo, Colorado, 81004

Recruiting
Site Public Contact · Contact
720-874-1881ResearchInstituteInquiries@CommonSpirit.org
Shahzad Siddique · Principal Investigator

Rocky Mountain Cancer Centers-Thornton

Thornton, Colorado, 80260

Active Not Recruiting

Saint Anthony North Hospital

Westminster, Colorado, 80023

Recruiting
Site Public Contact · Contact
720-874-1881ResearchInstituteInquiries@CommonSpirit.org
Shahzad Siddique · Principal Investigator

Sibley Memorial Hospital

Washington D.C., District of Columbia, 20016

Recruiting
Site Public Contact · Contact
202-243-2373jquiver1@jhmi.edu
Curtiland Deville · Principal Investigator

Moffitt Cancer Center-International Plaza

Tampa, Florida, 33607

Recruiting
Site Public Contact · Contact
800-679-0775ClinicalTrials@moffitt.org
Kosj Yamoah · Principal Investigator

Moffitt Cancer Center - McKinley Campus

Tampa, Florida, 33612

Recruiting
Site Public Contact · Contact
800-679-0775ClinicalTrials@moffitt.org
Kosj Yamoah · Principal Investigator

Moffitt Cancer Center

Tampa, Florida, 33612

Recruiting
Site Public Contact · Contact
800-679-0775ClinicalTrials@moffitt.org
Kosj Yamoah · Principal Investigator

Moffitt Cancer Center at Wesley Chapel

Wesley Chapel, Florida, 33544

Recruiting
Site Public Contact · Contact
800-679-0775ClinicalTrials@moffitt.org
Kosj Yamoah · Principal Investigator

Saint Alphonsus Cancer Care Center-Boise

Boise, Idaho, 83706

Suspended

Saint Luke's Cancer Institute - Boise

Boise, Idaho, 83712

Recruiting
Site Public Contact · Contact
208-381-2774eslinget@slhs.org
Alison K. Conlin · Principal Investigator

Saint Alphonsus Cancer Care Center-Caldwell

Caldwell, Idaho, 83605

Suspended

Kootenai Health - Coeur d'Alene

Coeur d'Alene, Idaho, 83814

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Saint Luke's Cancer Institute - Fruitland

Fruitland, Idaho, 83619

Recruiting
Site Public Contact · Contact
208-381-2774eslinget@slhs.org
Alison K. Conlin · Principal Investigator

Idaho Urologic Institute-Meridian

Meridian, Idaho, 83642

Suspended

Saint Luke's Cancer Institute - Meridian

Meridian, Idaho, 83642

Recruiting
Site Public Contact · Contact
208-381-2774eslinget@slhs.org
Alison K. Conlin · Principal Investigator

Saint Alphonsus Cancer Care Center-Nampa

Nampa, Idaho, 83687

Suspended

Saint Luke's Cancer Institute - Nampa

Nampa, Idaho, 83687

Recruiting
Site Public Contact · Contact
208-381-2774eslinget@slhs.org
Alison K. Conlin · Principal Investigator

Kootenai Clinic Cancer Services - Post Falls

Post Falls, Idaho, 83854

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Saint Luke's Cancer Institute - Twin Falls

Twin Falls, Idaho, 83301

Recruiting
Site Public Contact · Contact
208-381-2774eslinget@slhs.org
Alison K. Conlin · Principal Investigator

Alton Memorial Hospital

Alton, Illinois, 62002

Recruiting
Site Public Contact · Contact
618-463-7323
Jeff M. Michalski · Principal Investigator

OSF Saint Anthony's Health Center

Alton, Illinois, 62002

Recruiting
Site Public Contact · Contact
618-463-5623
Jay W. Carlson · Principal Investigator

Rush-Copley Medical Center

Aurora, Illinois, 60504

Recruiting
Site Public Contact · Contact
630-978-6212RCMC_Cancer_Research@rush.edu
Sinisa Stanic · Principal Investigator

Illinois CancerCare-Bloomington

Bloomington, Illinois, 61704

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

Illinois CancerCare-Canton

Canton, Illinois, 61520

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

Memorial Hospital of Carbondale

Carbondale, Illinois, 62902

Recruiting
Site Public Contact · Contact
618-457-5200clinical.research@sih.net
Bryan A. Faller · Principal Investigator

SIH Cancer Institute

Carterville, Illinois, 62918

Recruiting
Site Public Contact · Contact
618-985-3333clinical.research@sih.net
Bryan A. Faller · Principal Investigator

Illinois CancerCare-Carthage

Carthage, Illinois, 62321

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

Centralia Oncology Clinic

Centralia, Illinois, 62801

Recruiting
Site Public Contact · Contact
217-876-4762morganthaler.jodi@mhsil.com
Bryan A. Faller · Principal Investigator

Saint Mary's Hospital

Centralia, Illinois, 62801

Suspended

Northwestern University

Chicago, Illinois, 60611

Recruiting
Site Public Contact · Contact
312-695-1301cancer@northwestern.edu
Sean Sachdev · Principal Investigator

Rush MD Anderson Cancer Center

Chicago, Illinois, 60612

Recruiting
Site Public Contact · Contact
312-226-2371Cancer_Studies@rush.edu
Dian Wang · Principal Investigator

University of Illinois

Chicago, Illinois, 60612

Recruiting
Site Public Contact · Contact
312-355-3046
Daniel Moreira · Principal Investigator

Carle at The Riverfront

Danville, Illinois, 61832

Recruiting
Site Public Contact · Contact
800-446-5532Research@Carle.com
Sinisa Stanic · Principal Investigator

Cancer Care Specialists of Illinois - Decatur

Decatur, Illinois, 62526

Recruiting
Site Public Contact · Contact
217-876-4762morganthaler.jodi@mhsil.com
Bryan A. Faller · Principal Investigator

Decatur Memorial Hospital

Decatur, Illinois, 62526

Recruiting
Site Public Contact · Contact
217-876-4762morganthaler.jodi@mhsil.com
Bryan A. Faller · Principal Investigator

Northwestern Medicine Cancer Center Kishwaukee

DeKalb, Illinois, 60115

Recruiting
Site Public Contact · Contact
630-352-5360Donald.Smith3@nm.org
William F. Hartsell · Principal Investigator

Illinois CancerCare-Dixon

Dixon, Illinois, 61021

Suspended

Carle Physician Group-Effingham

Effingham, Illinois, 62401

Recruiting
Site Public Contact · Contact
800-446-5532Research@carle.com
Sinisa Stanic · Principal Investigator

Crossroads Cancer Center

Effingham, Illinois, 62401

Recruiting
Site Public Contact · Contact
217-876-4762morganthaler.jodi@mhsil.com
Bryan A. Faller · Principal Investigator

Illinois CancerCare-Eureka

Eureka, Illinois, 61530

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

Illinois CancerCare-Galesburg

Galesburg, Illinois, 61401

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

Western Illinois Cancer Treatment Center

Galesburg, Illinois, 61401

Suspended

Northwestern Medicine Cancer Center Delnor

Geneva, Illinois, 60134

Recruiting
Site Public Contact · Contact
630-352-5360Donald.Smith3@nm.org
William F. Hartsell · Principal Investigator

Illinois CancerCare-Kewanee Clinic

Kewanee, Illinois, 61443

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

Rush MD Anderson Cancer Center at Rush Lisle

Lisle, Illinois, 60532

Recruiting
Site Public Contact · Contact
312-226-2371Cancer_Studies@rush.edu
Dian Wang · Principal Investigator

Illinois CancerCare-Macomb

Macomb, Illinois, 61455

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

Carle Physician Group-Mattoon/Charleston

Mattoon, Illinois, 61938

Recruiting
Site Public Contact · Contact
800-446-5532Research@carle.com
Sinisa Stanic · Principal Investigator

Loyola University Medical Center

Maywood, Illinois, 60153

Active Not Recruiting

SSM Health Good Samaritan

Mount Vernon, Illinois, 62864

Recruiting
Site Public Contact · Contact
618-899-1894gayla.hall@ssmhealth.com
Jay W. Carlson · Principal Investigator

Cancer Care Center of O'Fallon

O'Fallon, Illinois, 62269

Recruiting
Site Public Contact · Contact
217-876-4762morganthaler.jodi@mhsil.com
Bryan A. Faller · Principal Investigator

HSHS Saint Elizabeth's Hospital

O'Fallon, Illinois, 62269

Recruiting
Site Public Contact · Contact
217-876-4762morganthaler.jodi@mhsil.com
Bryan A. Faller · Principal Investigator

Northwestern Medicine Oak Brook

Oak Brook, Illinois, 60523

Recruiting
Site Public Contact · Contact
nctnprogram_rhlccc@northwestern.edu
Sean Sachdev · Principal Investigator

Rush MD Anderson Cancer Center at Rush Oak Park

Oak Park, Illinois, 60304

Recruiting
Site Public Contact · Contact
312-226-2371Cancer_Studies@rush.edu
Dian Wang · Principal Investigator

Illinois CancerCare-Ottawa Clinic

Ottawa, Illinois, 61350

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

Illinois CancerCare-Pekin

Pekin, Illinois, 61554

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

Illinois CancerCare-Peoria

Peoria, Illinois, 61615

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

Methodist Medical Center of Illinois

Peoria, Illinois, 61636

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

Illinois CancerCare-Peru

Peru, Illinois, 61354

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

Valley Radiation Oncology

Peru, Illinois, 61354

Suspended

Illinois CancerCare-Princeton

Princeton, Illinois, 61356

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

UW Health Carbone Cancer Center Rockford

Rockford, Illinois, 61114

Recruiting
Site Public Contact · Contact
779-696-9378lkline@uwhealth.org
Fahrettin Covut · Principal Investigator

Southern Illinois University School of Medicine

Springfield, Illinois, 62702

Recruiting
Site Public Contact · Contact
217-545-7929
Bryan A. Faller · Principal Investigator

Springfield Clinic

Springfield, Illinois, 62702

Recruiting
Site Public Contact · Contact
800-444-7541
Bryan A. Faller · Principal Investigator

Springfield Memorial Hospital

Springfield, Illinois, 62781

Recruiting
Site Public Contact · Contact
217-528-7541pallante.beth@mhsil.com
Bryan A. Faller · Principal Investigator

Carle Cancer Center

Urbana, Illinois, 61801

Recruiting
Site Public Contact · Contact
800-446-5532Research@carle.com
Sinisa Stanic · Principal Investigator

The Carle Foundation Hospital

Urbana, Illinois, 61801

Recruiting
Site Public Contact · Contact
800-446-5532Research@carle.com
Sinisa Stanic · Principal Investigator

Northwestern Medicine Cancer Center Warrenville

Warrenville, Illinois, 60555

Recruiting
Site Public Contact · Contact
630-352-5360Donald.Smith3@nm.org
William F. Hartsell · Principal Investigator

Illinois CancerCare - Washington

Washington, Illinois, 61571

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

Mercy Hospital

Cedar Rapids, Iowa, 52403

Recruiting
Site Public Contact · Contact
319-365-4673
Deborah W. Wilbur · Principal Investigator

Oncology Associates at Mercy Medical Center

Cedar Rapids, Iowa, 52403

Recruiting
Site Public Contact · Contact
319-363-2690
Deborah W. Wilbur · Principal Investigator

Central Care Cancer Center - Garden City

Garden City, Kansas, 67846

Recruiting
Site Public Contact · Contact
913-948-5588aroland@kccop.org
Jay W. Carlson · Principal Investigator

Central Care Cancer Center - Great Bend

Great Bend, Kansas, 67530

Suspended

Mercy Hospital Pittsburg

Pittsburg, Kansas, 66762

Recruiting
Site Public Contact · Contact
888-446-3729
Jay W. Carlson · Principal Investigator

Saint Joseph Hospital

Lexington, Kentucky, 40504

Recruiting
Site Public Contact · Contact
720-874-1881ResearchInstituteInquiries@CommonSpirit.org
Shahzad Siddique · Principal Investigator

Saint Joseph Radiation Oncology Resource Center

Lexington, Kentucky, 40504

Recruiting
Site Public Contact · Contact
720-874-1881ResearchInstituteInquiries@CommonSpirit.org
Shahzad Siddique · Principal Investigator

Saint Joseph Hospital East

Lexington, Kentucky, 40509

Recruiting
Site Public Contact · Contact
720-874-1881ResearchInstituteInquiries@CommonSpirit.org
Shahzad Siddique · Principal Investigator

Jewish Hospital

Louisville, Kentucky, 40202

Suspended

LSU Health Baton Rouge-North Clinic

Baton Rouge, Louisiana, 70805

Recruiting
Site Public Contact · Contact
225-765-7659research@ololrmc.com
Marshall P. Stagg · Principal Investigator

Our Lady of the Lake Physician Group

Baton Rouge, Louisiana, 70808

Recruiting
Site Public Contact · Contact
225-765-7659research@ololrmc.com
Marshall P. Stagg · Principal Investigator

MaineHealth Coastal Cancer Treatment Center

Bath, Maine, 04530

Active Not Recruiting

MaineHealth Maine Medical Center - Biddeford

Biddeford, Maine, 04005

Active Not Recruiting

MaineHealth Maine Medical Center - Portland

Portland, Maine, 04102

Active Not Recruiting

MaineHealth Cancer Care and IV Therapy - Sanford

Sanford, Maine, 04073

Active Not Recruiting

MaineHealth Cancer Care Center of York County

Sanford, Maine, 04073

Active Not Recruiting

MaineHealth Maine Medical Center- Scarborough

Scarborough, Maine, 04074

Active Not Recruiting

MaineHealth Cancer Care and IV Therapy - South Portland

South Portland, Maine, 04106

Active Not Recruiting

University of Maryland/Greenebaum Cancer Center

Baltimore, Maryland, 21201

Active Not Recruiting

Johns Hopkins University/Sidney Kimmel Cancer Center

Baltimore, Maryland, 21287

Recruiting
Site Public Contact · Contact
410-955-8804jhcccro@jhmi.edu
Curtiland Deville · Principal Investigator

Suburban Hospital

Bethesda, Maryland, 20814

Recruiting
Site Public Contact · Contact
301-896-2719bsquill1@jhmi.edu
Curtiland Deville · Principal Investigator

UM Baltimore Washington Medical Center/Tate Cancer Center

Glen Burnie, Maryland, 21061

Active Not Recruiting

Minnesota Oncology - Burnsville

Burnsville, Minnesota, 55337

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
David M. King · Principal Investigator

Minnesota Oncology Hematology PA-Chaska

Chaska, Minnesota, 55318

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
David M. King · Principal Investigator

Mercy Hospital

Coon Rapids, Minnesota, 55433

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
David M. King · Principal Investigator

Minnesota Oncology - Coon Rapids

Coon Rapids, Minnesota, 55433

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
David M. King · Principal Investigator

Fairview Southdale Hospital

Edina, Minnesota, 55435

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
David M. King · Principal Investigator

Minnesota Oncology - Edina

Edina, Minnesota, 55435

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
David M. King · Principal Investigator

Unity Hospital

Fridley, Minnesota, 55432

Active Not Recruiting

Fairview Clinics and Surgery Center Maple Grove

Maple Grove, Minnesota, 55369

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
David M. King · Principal Investigator

Minnesota Oncology - Maple Grove

Maple Grove, Minnesota, 55369

Recruiting
Site Public Contact · Contact
952-993-1572mmcorc@healthpartners.com
David M. King · Principal Investigator

Minnesota Oncology Hematology PA-Maplewood

Maplewood, Minnesota, 55109

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
David M. King · Principal Investigator

Saint John's Hospital - Healtheast

Maplewood, Minnesota, 55109

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
David M. King · Principal Investigator

Abbott-Northwestern Hospital

Minneapolis, Minnesota, 55407

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
David M. King · Principal Investigator

Hennepin County Medical Center

Minneapolis, Minnesota, 55415

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
David M. King · Principal Investigator

Health Partners Inc

Minneapolis, Minnesota, 55454

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
David M. King · Principal Investigator

Monticello Cancer Center

Monticello, Minnesota, 55362

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
David M. King · Principal Investigator

North Memorial Medical Health Center

Robbinsdale, Minnesota, 55422

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
David M. King · Principal Investigator

Coborn Cancer Center at Saint Cloud Hospital

Saint Cloud, Minnesota, 56303

Recruiting
Site Public Contact · Contact
877-229-4907coborncancercenter@centracare.com
Donald J. Jurgens · Principal Investigator

Park Nicollet Clinic - Saint Louis Park

Saint Louis Park, Minnesota, 55416

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
David M. King · Principal Investigator

Regions Hospital

Saint Paul, Minnesota, 55101

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
David M. King · Principal Investigator

United Hospital

Saint Paul, Minnesota, 55102

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
David M. King · Principal Investigator

Saint Francis Regional Medical Center

Shakopee, Minnesota, 55379

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
David M. King · Principal Investigator

Lakeview Hospital

Stillwater, Minnesota, 55082

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
David M. King · Principal Investigator

Ridgeview Medical Center

Waconia, Minnesota, 55387

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
David M. King · Principal Investigator

Rice Memorial Hospital

Willmar, Minnesota, 56201

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
David M. King · Principal Investigator

Minnesota Oncology Hematology PA-Woodbury

Woodbury, Minnesota, 55125

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
David M. King · Principal Investigator

Baptist Cancer Center-Grenada

Grenada, Mississippi, 38901

Recruiting
Site Public Contact · Contact
901-226-1366BCCclintrials@bmhcc.org
Andrew J. Benefield · Principal Investigator

University of Mississippi Medical Center

Jackson, Mississippi, 39216

Active Not Recruiting

Baptist Memorial Hospital and Cancer Center-Union County

New Albany, Mississippi, 38652

Recruiting
Site Public Contact · Contact
901-226-1366BCCclintrials@bmhcc.org
Andrew J. Benefield · Principal Investigator

Baptist Memorial Hospital and Cancer Center-Oxford

Oxford, Mississippi, 38655

Recruiting
Site Public Contact · Contact
901-226-1366BCCclintrials@bmhcc.org
Andrew J. Benefield · Principal Investigator

Central Care Cancer Center - Bolivar

Bolivar, Missouri, 65613

Recruiting
Site Public Contact · Contact
913-948-5588aroland@kccop.org
Jay W. Carlson · Principal Investigator

Mercy Cancer Center - Cape Girardeau

Cape Girardeau, Missouri, 63703

Recruiting
Site Public Contact · Contact
888-446-3729
Jay W. Carlson · Principal Investigator

Saint Francis Medical Center

Cape Girardeau, Missouri, 63703

Recruiting
Site Public Contact · Contact
573-334-2230sfmc@sfmc.net
Bryan A. Faller · Principal Investigator

Siteman Cancer Center at Saint Peters Hospital

City of Saint Peters, Missouri, 63376

Recruiting
Site Public Contact · Contact
800-600-3606info@siteman.wustl.edu
Jeff M. Michalski · Principal Investigator

Siteman Cancer Center at West County Hospital

Creve Coeur, Missouri, 63141

Recruiting
Site Public Contact · Contact
800-600-3606info@siteman.wustl.edu
Jeff M. Michalski · Principal Investigator

Parkland Health Center - Farmington

Farmington, Missouri, 63640

Recruiting
Site Public Contact · Contact
314-996-5569
Bryan A. Faller · Principal Investigator

MU Health Care Goldschmidt Cancer Center

Jefferson City, Missouri, 65109

Suspended

Freeman Health System

Joplin, Missouri, 64804

Recruiting
Site Public Contact · Contact
417-347-4030LJCrockett@freemanhealth.com
Jay W. Carlson · Principal Investigator

Mercy Hospital Joplin

Joplin, Missouri, 64804

Recruiting
Site Public Contact · Contact
417-556-3074esmeralda.carrillo@mercy.net
Jay W. Carlson · Principal Investigator

Lake Regional Hospital

Osage Beach, Missouri, 65065

Recruiting
Site Public Contact · Contact
573-302-2768clinicaltrials@lakeregional.com
Jay W. Carlson · Principal Investigator

Mercy Clinic-Rolla-Cancer and Hematology

Rolla, Missouri, 65401

Recruiting
Site Public Contact · Contact
573-458-6379
Jay W. Carlson · Principal Investigator

Phelps Health Delbert Day Cancer Institute

Rolla, Missouri, 65401

Recruiting
Site Public Contact · Contact
573-458-7504research@phelpshealth.org
Jay W. Carlson · Principal Investigator

Heartland Regional Medical Center

Saint Joseph, Missouri, 64506

Recruiting
Site Public Contact · Contact
816-271-7937Trisha.England2@mymlc.com
Jay W. Carlson · Principal Investigator

Sainte Genevieve County Memorial Hospital

Sainte Genevieve, Missouri, 63670

Recruiting
Site Public Contact · Contact
314-996-5569
Bryan A. Faller · Principal Investigator

Mercy Hospital Springfield

Springfield, Missouri, 65804

Recruiting
Site Public Contact · Contact
417-269-4520
Jay W. Carlson · Principal Investigator

CoxHealth South Hospital

Springfield, Missouri, 65807

Recruiting
Site Public Contact · Contact
417-269-4520
Jay W. Carlson · Principal Investigator

Washington University School of Medicine

St Louis, Missouri, 63110

Recruiting
Site Public Contact · Contact
800-600-3606info@siteman.wustl.edu
Jeff M. Michalski · Principal Investigator

Mercy Hospital South

St Louis, Missouri, 63128

Recruiting
Site Public Contact · Contact
314-525-6042Danielle.Werle@mercy.net
Jay W. Carlson · Principal Investigator

Siteman Cancer Center-South County

St Louis, Missouri, 63129

Recruiting
Site Public Contact · Contact
800-600-3606info@siteman.wustl.edu
Jeff M. Michalski · Principal Investigator

Missouri Baptist Medical Center

St Louis, Missouri, 63131

Recruiting
Site Public Contact · Contact
314-996-5569
Bryan A. Faller · Principal Investigator

Siteman Cancer Center at Christian Hospital

St Louis, Missouri, 63136

Recruiting
Site Public Contact · Contact
800-600-3606info@siteman.wustl.edu
Jeff M. Michalski · Principal Investigator

Mercy Hospital Saint Louis

St Louis, Missouri, 63141

Recruiting
Site Public Contact · Contact
314-251-7066
Jay W. Carlson · Principal Investigator

Missouri Baptist Sullivan Hospital

Sullivan, Missouri, 63080

Recruiting
Site Public Contact · Contact
314-996-5569
Bryan A. Faller · Principal Investigator

BJC Outpatient Center at Sunset Hills

Sunset Hills, Missouri, 63127

Recruiting
Site Public Contact · Contact
314-996-5569
Bryan A. Faller · Principal Investigator

Billings Clinic Cancer Center

Billings, Montana, 59101

Recruiting
Site Public Contact · Contact
800-996-2663research@billingsclinic.org
John M. Schallenkamp · Principal Investigator

Bozeman Health Deaconess Hospital

Bozeman, Montana, 59715

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Benefis Sletten Cancer Institute

Great Falls, Montana, 59405

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Great Falls Clinic

Great Falls, Montana, 59405

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Hi-Line Sletten Cancer Center

Havre, Montana, 59501

Recruiting
Site Public Contact · Contact
ecog.rss@jimmy.harvard.edu
John M. Schallenkamp · Principal Investigator

Logan Health Medical Center

Kalispell, Montana, 59901

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Saint Patrick Hospital - Community Hospital

Missoula, Montana, 59802

Recruiting
Site Public Contact · Contact
406-327-3118amy.hanneman@providence.org
Alison K. Conlin · Principal Investigator

Community Medical Center

Missoula, Montana, 59804

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

CHI Health Good Samaritan

Kearney, Nebraska, 68847

Recruiting
Site Public Contact · Contact
720-874-1881ResearchInstituteInquiries@CommonSpirit.org
Shahzad Siddique · Principal Investigator

Alegent Health Immanuel Medical Center

Omaha, Nebraska, 68122

Suspended

Alegent Health Bergan Mercy Medical Center

Omaha, Nebraska, 68124

Recruiting
Site Public Contact · Contact
720-874-1881ResearchInstituteInquiries@CommonSpirit.org
Shahzad Siddique · Principal Investigator

Alegent Health Lakeside Hospital

Omaha, Nebraska, 68130

Suspended

Creighton University Medical Center

Omaha, Nebraska, 68131

Recruiting
Site Public Contact · Contact
720-874-1881ResearchInstituteInquiries@CommonSpirit.org
Shahzad Siddique · Principal Investigator

Cooper Hospital University Medical Center

Camden, New Jersey, 08103

Recruiting
Site Public Contact · Contact
856-325-6757
Gary Eastwick · Principal Investigator

Hackensack University Medical Center

Hackensack, New Jersey, 07601

Active Not Recruiting

Rutgers Cancer Institute of New Jersey

New Brunswick, New Jersey, 08903

Recruiting
Site Public Contact · Contact
732-235-7356
Tina Mayer · Principal Investigator

Robert Wood Johnson University Hospital Somerset

Somerville, New Jersey, 08876

Recruiting
Site Public Contact · Contact
908-685-2481Siby.Varughese@rwjbh.org
Tina Mayer · Principal Investigator

Community Medical Center

Toms River, New Jersey, 08755

Recruiting
Site Public Contact · Contact
732-557-8294Lennette.Gonzales@rwjbh.org
Tina Mayer · Principal Investigator

MD Anderson Cancer Center at Cooper-Voorhees

Voorhees Township, New Jersey, 08043

Recruiting
Site Public Contact · Contact
856-325-6757
Gary Eastwick · Principal Investigator

Northwell Health Imbert Cancer Center

Bay Shore, New York, 11706

Recruiting
Site Public Contact · Contact
516-734-8896
Clary Evans · Principal Investigator

Northwell Health Physicians Partners Radiation Medicine at Queens

Forest Hills, New York, 11375

Recruiting
Site Public Contact · Contact
718-520-6620
Clary Evans · Principal Investigator

Northwell Health/Center for Advanced Medicine

Lake Success, New York, 11042

Recruiting
Site Public Contact · Contact
516-734-8896
Clary Evans · Principal Investigator

Mount Sinai Union Square

New York, New York, 10003

Recruiting
Site Public Contact · Contact
212-824-7309CCTO@mssm.edu
Bobby Liaw · Principal Investigator

Mount Sinai Chelsea

New York, New York, 10011

Recruiting
Site Public Contact · Contact
212-824-7309CCTO@mssm.edu
Bobby Liaw · Principal Investigator

Mount Sinai West

New York, New York, 10019

Recruiting
Site Public Contact · Contact
212-824-7309CCTO@mssm.edu
Bobby Liaw · Principal Investigator

Mount Sinai Hospital

New York, New York, 10029

Recruiting
Site Public Contact · Contact
212-824-7309CCTO@mssm.edu
Bobby Liaw · Principal Investigator

New York Proton Center

New York, New York, 10035

Recruiting
Site Public Contact · Contact
646-968-9031ichoi@nyproton.com
Irini Yacoub · Principal Investigator

Manhattan Eye Ear and Throat Hospital

New York, New York, 10065

Recruiting
Site Public Contact · Contact
212-434-4460
Clary Evans · Principal Investigator

Lenox Hill Hospital

New York, New York, 10075

Recruiting
Site Public Contact · Contact
516-734-8896
Clary Evans · Principal Investigator

Queens Cancer Center

Rego Park, New York, 11374

Recruiting
Site Public Contact · Contact
718-312-3446
Clary Evans · Principal Investigator

Phelps Memorial Hospital Center

Sleepy Hollow, New York, 10591

Recruiting
Site Public Contact · Contact
914-366-1600
Clary Evans · Principal Investigator

Stony Brook University Medical Center

Stony Brook, New York, 11794

Recruiting
Site Public Contact · Contact
800-862-2215
Jieying Wu · Principal Investigator

Montefiore Medical Center-Einstein Campus

The Bronx, New York, 10461

Recruiting
Site Public Contact · Contact
718-379-6866eskwak@montefiore.org
Benjamin A. Gartrell · Principal Investigator

Montefiore Medical Center-Weiler Hospital

The Bronx, New York, 10461

Recruiting
Site Public Contact · Contact
718-379-6866eskwak@montefiore.org
Benjamin A. Gartrell · Principal Investigator

Montefiore Medical Center - Moses Campus

The Bronx, New York, 10467

Recruiting
Site Public Contact · Contact
718-379-6866eskwak@montefiore.org
Benjamin A. Gartrell · Principal Investigator

Westchester Medical Center

Valhalla, New York, 10595

Recruiting
Site Public Contact · Contact
888-823-5923ctsucontact@westat.com
Mark D. Hurwitz · Principal Investigator

ECU Health Oncology Kenansville

Kenansville, North Carolina, 28349

Suspended

ECU Health Oncology Kinston

Kinston, North Carolina, 28501

Recruiting
Site Public Contact · Contact
252-559-2201research@ecuhealth.org
Haritha Ackula · Principal Investigator

ECU Health Oncology Richlands

Richlands, North Carolina, 28574

Suspended

University of Cincinnati Cancer Center-UC Medical Center

Cincinnati, Ohio, 45219

Active Not Recruiting

Good Samaritan Hospital - Cincinnati

Cincinnati, Ohio, 45220

Recruiting
Site Public Contact · Contact
720-874-1881ResearchInstituteInquiries@CommonSpirit.org
Shahzad Siddique · Principal Investigator

Bethesda North Hospital

Cincinnati, Ohio, 45242

Recruiting
Site Public Contact · Contact
720-874-1881ResearchInstituteInquiries@CommonSpirit.org
Shahzad Siddique · Principal Investigator

Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210

Recruiting
Site Public Contact · Contact
800-293-5066Jamesline@osumc.edu
Shang-Jui Wang · Principal Investigator

University of Cincinnati Cancer Center-West Chester

West Chester, Ohio, 45069

Active Not Recruiting

University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, 73104

Recruiting
Site Public Contact · Contact
405-271-8777ou-clinical-trials@ouhsc.edu
Tyler Gunter · Principal Investigator

Mercy Hospital Oklahoma City

Oklahoma City, Oklahoma, 73120

Recruiting
Site Public Contact · Contact
405-752-3402
Jay W. Carlson · Principal Investigator

Saint Charles Health System

Bend, Oregon, 97701

Recruiting
Site Public Contact · Contact
541-706-2909nosall@stcharleshealthcare.org
Alison K. Conlin · Principal Investigator

Clackamas Radiation Oncology Center

Clackamas, Oregon, 97015

Recruiting
Site Public Contact · Contact
503-215-2614CanRsrchStudies@providence.org
Alison K. Conlin · Principal Investigator

Providence Cancer Institute Clackamas Clinic

Clackamas, Oregon, 97015

Suspended

Bay Area Hospital

Coos Bay, Oregon, 97420

Recruiting
Site Public Contact · Contact
541-269-8392cherie.cox@bayareahospital.org
Alison K. Conlin · Principal Investigator

Legacy Mount Hood Medical Center

Gresham, Oregon, 97030

Active Not Recruiting

Providence Newberg Medical Center

Newberg, Oregon, 97132

Recruiting
Site Public Contact · Contact
503-215-2614CanRsrchStudies@providence.org
Alison K. Conlin · Principal Investigator

Providence Willamette Falls Medical Center

Oregon City, Oregon, 97045

Recruiting
Site Public Contact · Contact
503-215-2614CanRsrchStudies@providence.org
Alison K. Conlin · Principal Investigator

Legacy Good Samaritan Hospital and Medical Center

Portland, Oregon, 97210

Active Not Recruiting

Providence Portland Medical Center

Portland, Oregon, 97213

Recruiting
Site Public Contact · Contact
503-215-2614CanRsrchStudies@providence.org
Alison K. Conlin · Principal Investigator

Providence Saint Vincent Medical Center

Portland, Oregon, 97225

Recruiting
Site Public Contact · Contact
503-215-2614CanRsrchStudies@providence.org
Alison K. Conlin · Principal Investigator

Oregon Health and Science University

Portland, Oregon, 97239

Recruiting
Site Public Contact · Contact
503-494-1080trials@ohsu.edu
Arthur Y. Hung · Principal Investigator

Legacy Meridian Park Hospital

Tualatin, Oregon, 97062

Active Not Recruiting

UPMC Altoona

Altoona, Pennsylvania, 16601

Recruiting
Site Public Contact · Contact
ecog.rss@jimmy.harvard.edu
Adam Olson · Principal Investigator

UPMC-Heritage Valley Health System Beaver

Beaver, Pennsylvania, 15009

Recruiting
Site Public Contact · Contact
412-389-5208haneydl@upmc.edu
Adam Olson · Principal Investigator

Crozer-Keystone Regional Cancer Center at Broomall

Broomall, Pennsylvania, 19008

Active Not Recruiting

Carlisle Regional Cancer Center

Carlisle, Pennsylvania, 17015

Recruiting
Site Public Contact · Contact
ecog.rss@jimmy.harvard.edu
Adam Olson · Principal Investigator

Delaware County Memorial Hospital

Drexel Hill, Pennsylvania, 19026

Active Not Recruiting

Fox Chase Cancer Center - East Norriton Hospital Outpatient Center

East Norriton, Pennsylvania, 19401

Active Not Recruiting

UPMC Hillman Cancer Center Erie

Erie, Pennsylvania, 16505

Recruiting
Site Public Contact · Contact
412-864-7716ClinicalResearchServices@upmc.edu
Adam Olson · Principal Investigator

UPMC Cancer Center at UPMC Horizon

Farrell, Pennsylvania, 16121

Recruiting
Site Public Contact · Contact
ecog.rss@jimmy.harvard.edu
Adam Olson · Principal Investigator

Fox Chase Cancer Center Buckingham

Furlong, Pennsylvania, 18925

Active Not Recruiting

Crozer Regional Cancer Center at Brinton Lake

Glen Mills, Pennsylvania, 19342

Active Not Recruiting

UPMC Cancer Centers - Arnold Palmer Pavilion

Greensburg, Pennsylvania, 15601

Recruiting
Site Public Contact · Contact
724-838-1900
Adam Olson · Principal Investigator

UPMC Pinnacle Cancer Center/Community Osteopathic Campus

Harrisburg, Pennsylvania, 17109

Recruiting
Site Public Contact · Contact
717-724-6765klitchfield@PINNACLEHEALTH.org
Adam Olson · Principal Investigator

Penn State Milton S Hershey Medical Center

Hershey, Pennsylvania, 17033-0850

Recruiting
Site Public Contact · Contact
717-531-3779CTO@hmc.psu.edu
Joseph A. Miccio · Principal Investigator

UPMC-Johnstown/John P. Murtha Regional Cancer Center

Johnstown, Pennsylvania, 15901

Recruiting
Site Public Contact · Contact
814-534-4724
Adam Olson · Principal Investigator

UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion

Mechanicsburg, Pennsylvania, 17050

Recruiting
Site Public Contact · Contact
412-389-5208haneydl@upmc.edu
Adam Olson · Principal Investigator

UPMC Cancer Center - Monroeville

Monroeville, Pennsylvania, 15146

Recruiting
Site Public Contact · Contact
ecog.rss@jimmy.harvard.edu
Adam Olson · Principal Investigator

UPMC Hillman Cancer Center in Coraopolis

Moon Township, Pennsylvania, 15108

Recruiting
Site Public Contact · Contact
412-389-5208haneydl@upmc.edu
Adam Olson · Principal Investigator

UPMC Cancer Center-Natrona Heights

Natrona Heights, Pennsylvania, 15065

Recruiting
Site Public Contact · Contact
724-230-3030
Adam Olson · Principal Investigator

UPMC Hillman Cancer Center - New Castle

New Castle, Pennsylvania, 16105

Recruiting
Site Public Contact · Contact
412-389-5208haneydl@upmc.edu
Adam Olson · Principal Investigator

Penn Presbyterian Medical Center

Philadelphia, Pennsylvania, 19104

Recruiting
Site Public Contact · Contact
215-349-8245PMCancerResearch@pennmedicine.upenn.edu
Neha Vapiwala · Principal Investigator

University of Pennsylvania/Abramson Cancer Center

Philadelphia, Pennsylvania, 19104

Recruiting
Site Public Contact · Contact
215-349-8245PMCancerResearch@pennmedicine.upenn.edu
Neha Vapiwala · Principal Investigator

Thomas Jefferson University Hospital

Philadelphia, Pennsylvania, 19107

Recruiting
Site Public Contact · Contact
215-600-9151ONCTrialNow@jefferson.edu
Jessie W. Dinome · Principal Investigator

Fox Chase Cancer Center

Philadelphia, Pennsylvania, 19111

Active Not Recruiting

Temple University Hospital

Philadelphia, Pennsylvania, 19140

Active Not Recruiting

UPMC-Magee Womens Hospital

Pittsburgh, Pennsylvania, 15213

Recruiting
Site Public Contact · Contact
412-647-2811
Adam Olson · Principal Investigator

UPMC-Saint Margaret

Pittsburgh, Pennsylvania, 15215

Recruiting
Site Public Contact · Contact
412-784-4900
Adam Olson · Principal Investigator

University of Pittsburgh Cancer Institute (UPCI)

Pittsburgh, Pennsylvania, 15232

Recruiting
Site Public Contact · Contact
412-647-8073
Adam Olson · Principal Investigator

UPMC-Shadyside Hospital

Pittsburgh, Pennsylvania, 15232

Recruiting
Site Public Contact · Contact
412-621-2334
Adam Olson · Principal Investigator

UPMC-Passavant Hospital

Pittsburgh, Pennsylvania, 15237

Recruiting
Site Public Contact · Contact
412-367-6454
Adam Olson · Principal Investigator

UPMC-Saint Clair Hospital Cancer Center

Pittsburgh, Pennsylvania, 15243

Recruiting
Site Public Contact · Contact
412-502-3920
Adam Olson · Principal Investigator

UPMC Cancer Center at UPMC Northwest

Seneca, Pennsylvania, 16346

Recruiting
Site Public Contact · Contact
814-676-7900
Adam Olson · Principal Investigator

UPMC Cancer Center-Uniontown

Uniontown, Pennsylvania, 15401

Recruiting
Site Public Contact · Contact
ecog.rss@jimmy.harvard.edu
Adam Olson · Principal Investigator

UPMC Uniontown Hospital Radiation Oncology

Uniontown, Pennsylvania, 15401

Recruiting
Site Public Contact · Contact
724-437-2503
Adam Olson · Principal Investigator

UPMC Washington Hospital Radiation Oncology

Washington, Pennsylvania, 15301

Recruiting
Site Public Contact · Contact
724-223-3788cancer@washingtonhospital.org
Adam Olson · Principal Investigator

UPMC Susquehanna

Williamsport, Pennsylvania, 17701

Recruiting
Site Public Contact · Contact
800-598-4282
Adam Olson · Principal Investigator

UPMC Memorial

York, Pennsylvania, 17408

Recruiting
Site Public Contact · Contact
717-724-6760
Adam Olson · Principal Investigator

Medical University of South Carolina

Charleston, South Carolina, 29425

Recruiting
Site Public Contact · Contact
843-792-9321hcc-clinical-trials@musc.edu
Harriet B. Eldredge-Hindy · Principal Investigator

Sanford Cancer Center Oncology Clinic

Sioux Falls, South Dakota, 57104

Suspended

Sanford USD Medical Center - Sioux Falls

Sioux Falls, South Dakota, 57117-5134

Suspended

Parkland Memorial Hospital

Dallas, Texas, 75235

Recruiting
Site Public Contact · Contact
214-590-5582canceranswerline@UTSouthwestern.edu
Kevin D. Courtney · Principal Investigator

UT Southwestern Simmons Cancer Center - RedBird

Dallas, Texas, 75237

Recruiting
Site Public Contact · Contact
214-648-7097canceranswerline@utsouthwestern.edu
Kevin D. Courtney · Principal Investigator

UT Southwestern/Simmons Cancer Center-Dallas

Dallas, Texas, 75390

Recruiting
Site Public Contact · Contact
214-648-7097canceranswerline@UTSouthwestern.edu
Kevin D. Courtney · Principal Investigator

Tarrant County Hospital District/JPS Health Network

Fort Worth, Texas, 76104

Recruiting
Site Public Contact · Contact
817-702-5913macosta02@jpshealth.org
Marta Dahiya · Principal Investigator

UT Southwestern/Simmons Cancer Center-Fort Worth

Fort Worth, Texas, 76104

Recruiting
Site Public Contact · Contact
214-648-7097canceranswerline@UTSouthwestern.edu
Kevin D. Courtney · Principal Investigator

UT Southwestern Clinical Center at Richardson/Plano

Richardson, Texas, 75080

Recruiting
Site Public Contact · Contact
972-669-7044Suzanne.cole@utsouthwestern.edu
Kevin D. Courtney · Principal Investigator

Audie L Murphy VA Hospital

San Antonio, Texas, 78229

Active Not Recruiting

University of Texas Health Science Center at San Antonio

San Antonio, Texas, 78229

Active Not Recruiting

University of Virginia Cancer Center

Charlottesville, Virginia, 22908

Recruiting
Site Public Contact · Contact
434-243-6303uvacancertrials@hscmail.mcc.virginia.edu
Michael E. Devitt · Principal Investigator

VCU Massey Comprehensive Cancer Center

Richmond, Virginia, 23298

Recruiting
Site Public Contact · Contact
804-628-6430CTOclinops@vcu.edu
Alfredo I. Urdaneta · Principal Investigator

Providence Regional Cancer System-Aberdeen

Aberdeen, Washington, 98520

Recruiting
Site Public Contact · Contact
360-412-8958deidre.dillon@providence.org
Alison K. Conlin · Principal Investigator

PeaceHealth Saint Joseph Medical Center

Bellingham, Washington, 98225

Recruiting
Site Public Contact · Contact
360-788-8223achapman1@peacehealth.org
Alison K. Conlin · Principal Investigator

Providence Regional Cancer System-Centralia

Centralia, Washington, 98531

Recruiting
Site Public Contact · Contact
360-412-8958deidre.dillon@providence.org
Alison K. Conlin · Principal Investigator

Swedish Cancer Institute-Edmonds

Edmonds, Washington, 98026

Recruiting
Site Public Contact · Contact
206-215-2343PCRC-NCORP@Swedish.org
Alison K. Conlin · Principal Investigator

Providence Regional Cancer Partnership

Everett, Washington, 98201

Recruiting
Site Public Contact · Contact
425-261-3529marilyn.birchman@providence.org
Alison K. Conlin · Principal Investigator

Swedish Cancer Institute-Issaquah

Issaquah, Washington, 98029

Recruiting
Site Public Contact · Contact
206-215-2343PCRC-NCORP@Swedish.org
Alison K. Conlin · Principal Investigator

Kadlec Clinic Hematology and Oncology

Kennewick, Washington, 99336

Recruiting
Site Public Contact · Contact
509-783-4637research@kadlecmed.org
Alison K. Conlin · Principal Investigator

Providence Regional Cancer System-Lacey

Lacey, Washington, 98503

Recruiting
Site Public Contact · Contact
360-412-8958deidre.dillon@providence.org
Alison K. Conlin · Principal Investigator

PeaceHealth Saint John Medical Center

Longview, Washington, 98632

Recruiting
Site Public Contact · Contact
360-514-2016kmakin-bond@peacehealth.org
Alison K. Conlin · Principal Investigator

Skagit Regional Health Cancer Care Center

Mount Vernon, Washington, 98274

Recruiting
Site Public Contact · Contact
360-814-2182rcccclinicalresearch@skagitvalleyhospital.org
Alison K. Conlin · Principal Investigator

Swedish Medical Center-Ballard Campus

Seattle, Washington, 98107

Recruiting
Site Public Contact · Contact
206-215-3086PCRC-NCORP@Swedish.org
Alison K. Conlin · Principal Investigator

Fred Hutchinson Cancer Center

Seattle, Washington, 98109

Recruiting
Site Public Contact · Contact
800-804-8824
Jonathan J. Chen · Principal Investigator

Swedish Medical Center-Cherry Hill

Seattle, Washington, 98122-5711

Recruiting
Site Public Contact · Contact
206-215-3086PCRC-NCORP@Swedish.org
Alison K. Conlin · Principal Investigator

Swedish Medical Center-First Hill

Seattle, Washington, 98122

Recruiting
Site Public Contact · Contact
206-215-2343PCRC-NCORP@Swedish.org
Alison K. Conlin · Principal Investigator

FHCC at Northwest Hospital

Seattle, Washington, 98133

Recruiting
Site Public Contact · Contact
206-606-5800
Jonathan J. Chen · Principal Investigator

University of Washington Medical Center - Montlake

Seattle, Washington, 98195

Recruiting
Site Public Contact · Contact
800-804-8824
Jonathan J. Chen · Principal Investigator

PeaceHealth United General Medical Center

Sedro-Woolley, Washington, 98284

Recruiting
Site Public Contact · Contact
360-788-8239achapman1@peacehealth.org
Alison K. Conlin · Principal Investigator

Saint Michael Cancer Center

Silverdale, Washington, 98383

Recruiting
Site Public Contact · Contact
720-874-1881ResearchInstituteInquiries@CommonSpirit.org
Shahzad Siddique · Principal Investigator

Cancer Care Northwest - Spokane South

Spokane, Washington, 99202

Recruiting
Site Public Contact · Contact
509-228-1680research@ccnw.net
Alison K. Conlin · Principal Investigator

Cancer Care Northwest-North Spokane

Spokane, Washington, 99218

Recruiting
Site Public Contact · Contact
509-228-1680research@ccnw.net
Alison K. Conlin · Principal Investigator

PeaceHealth Southwest Medical Center

Vancouver, Washington, 98664

Recruiting
Site Public Contact · Contact
360-514-3940kmakin-bond@peacehealth.org
Alison K. Conlin · Principal Investigator

Legacy Cancer Institute Medical Oncology and Day Treatment

Vancouver, Washington, 98684

Active Not Recruiting

Legacy Salmon Creek Hospital

Vancouver, Washington, 98686

Active Not Recruiting

Providence Saint Mary Regional Cancer Center

Walla Walla, Washington, 99362

Recruiting
Site Public Contact · Contact
509-897-5993Cheryl.Dodd@providence.org
Alison K. Conlin · Principal Investigator

Langlade Hospital and Cancer Center

Antigo, Wisconsin, 54409

Recruiting
Site Public Contact · Contact
715-623-9869Juli.Alford@aspirus.org
Andrew J. Huang · Principal Investigator

Marshfield Medical Center-EC Cancer Center

Eau Claire, Wisconsin, 54701

Recruiting
Site Public Contact · Contact
800-782-8581oncology.clinical.trials@marshfieldresearch.org
Isaac K. Yeboah · Principal Investigator

University of Wisconsin Carbone Cancer Center - Johnson Creek

Johnson Creek, Wisconsin, 53038

Recruiting
Site Public Contact · Contact
800-622-8922clinicaltrials@cancer.wisc.edu
John M. Floberg · Principal Investigator

William S Middleton VA Medical Center

Madison, Wisconsin, 53705

Recruiting
Site Public Contact · Contact
608-256-1901
Jessica M. Schuster · Principal Investigator

University of Wisconsin Carbone Cancer Center - Eastpark Medical Center

Madison, Wisconsin, 53718

Recruiting
Site Public Contact · Contact
800-622-8922clinicaltrials@cancer.wisc.edu
John M. Floberg · Principal Investigator

University of Wisconsin Carbone Cancer Center - University Hospital

Madison, Wisconsin, 53792

Recruiting
Site Public Contact · Contact
800-622-8922clinicaltrials@cancer.wisc.edu
John M. Floberg · Principal Investigator

Marshfield Medical Center-Marshfield

Marshfield, Wisconsin, 54449

Recruiting
Site Public Contact · Contact
800-782-8581oncology.clinical.trials@marshfieldresearch.org
Isaac K. Yeboah · Principal Investigator

Marshfield Medical Center - Minocqua

Minocqua, Wisconsin, 54548

Recruiting
Site Public Contact · Contact
800-782-8581oncology.clinical.trials@marshfieldresearch.org
Isaac K. Yeboah · Principal Investigator

Cancer Center of Western Wisconsin

New Richmond, Wisconsin, 54017

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
David M. King · Principal Investigator

Aspirus Cancer Care - James Beck Cancer Center

Rhinelander, Wisconsin, 54501

Recruiting
Site Public Contact · Contact
715-847-2353Beth.Knetter@aspirus.org
Andrew J. Huang · Principal Investigator

Marshfield Medical Center-Rice Lake

Rice Lake, Wisconsin, 54868

Recruiting
Site Public Contact · Contact
800-782-8581oncology.clinical.trials@marshfieldresearch.org
Isaac K. Yeboah · Principal Investigator

Aspirus Cancer Care - Stevens Point

Stevens Point, Wisconsin, 54481

Recruiting
Site Public Contact · Contact
715-847-2353Beth.Knetter@aspirus.org
Andrew J. Huang · Principal Investigator

Marshfield Medical Center-River Region at Stevens Point

Stevens Point, Wisconsin, 54482

Recruiting
Site Public Contact · Contact
800-782-8581oncology.clinical.trials@marshfieldresearch.org
Isaac K. Yeboah · Principal Investigator

Aspirus Regional Cancer Center

Wausau, Wisconsin, 54401

Recruiting
Site Public Contact · Contact
877-405-6866
Andrew J. Huang · Principal Investigator

Marshfield Medical Center - Weston

Weston, Wisconsin, 54476

Recruiting
Site Public Contact · Contact
800-782-8581oncology.clinical.trials@marshfieldresearch.org
Isaac K. Yeboah · Principal Investigator

Aspirus Cancer Care - Wisconsin Rapids

Wisconsin Rapids, Wisconsin, 54494

Recruiting
Site Public Contact · Contact
715-422-7718
Andrew J. Huang · Principal Investigator

Memorial Hospital of Laramie County

Cheyenne, Wyoming, 82001

Recruiting
Site Public Contact · Contact
ecog.rss@jimmy.harvard.edu
John M. Schallenkamp · Principal Investigator

Welch Cancer Center

Sheridan, Wyoming, 82801

Suspended

References

  • Morgan TM, Boorjian SA, Buyyounouski MK, Chapin BF, Chen DYT, Cheng HH, Chou R, Jacene HA, Kamran SC, Kim SK, Kirkby E, Luckenbaugh AN, Nathanson BJ, Nyame YA, Posadas EM, Tran PT, Chen RC. Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part II: Treatment Delivery for Non-metastatic Biochemical Recurrence After Primary Radical Prostatectomy. J Urol. 2024 Apr;211(4):518-525. doi: 10.1097/JU.0000000000003891. Epub 2024 Feb 29.(PubMed)
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging | Cancerify